ObjectiveThe role of ferroptosis-related genes in the occurrence and development of lung injury caused by sepsis was investigated by bioinformatics methods, and the closely related genes were predicted. MethodsThe Dataset GSE154653 was downloaded from the gene expression database (GEO), and a total of 8 cases of microarray gene set were included in normal group and lipopolysaccharide (LPS)-induced sepsis lung tissue. The differential expression genes (DEGs) were screened out under conditions of |log2 FC|>1 and P.adj<0.05. Meanwhile, the selected DEGs were combined with the driver and suppressor genes of ferroptosis downloaded from the ferroptosis database (FerrDb) to obtain the differential genes associated with ferroptosis in sepsis (Fe-DEGs). These Fe-DEGs were further analyzed using R language, DAVID, and STRING online tools to identify GO-KEGG functions and pathways, and the construction of PPI network. Results The Bioinformatics approach screened out 3533 DEGs and intersected 53 key genes related to ferroptosis. The further biological process (BP) of GO enrichment analysis mainly involves the positive regulation of transcription, the positive regulation of RNA polymerase II promoter transcription, the cytokine mediated signaling pathway, and the positive regulation of angiogenesis. The molecular function (MF) mainly involves the same protein binding, transcriptional activation activity and REDOX enzyme activity. The pathways are enriched in iron death, HIF-1 signaling pathway and AGE-RAGE signaling pathway. Five key Fe-DEGs genes were screened by constructing PPI network, including CYBB, LCN2, HMOX1, TIMP1 and CDKN1A. Conclusion CYBB、LCN2、HMOX1、TIMP1 and CDKNIA genes may be key genes involved in ferroptosis of lung tissue caused by sepsis.
目的 探討可調節負壓引流技術結合植皮治療皮膚缺損伴感染創面的臨床效果及護理要點。 方法 對2008年5月－2011年5月收治的106例皮膚缺損伴感染創面患者，采用間歇負壓引流治療3～10 d，負壓值設為50～120 mm Hg（1 mm Hg=0.133 kPa），創面達到Ⅱ期植皮條件時，采用大張、網狀或郵票狀皮片覆蓋創面，繼續采用持續負壓引流治療3～12 d，負壓值設為50～60 mm Hg，同時進行患者心理和可調節負壓引流技術創面等護理。 結果 56例大張皮片植皮中，2例皮片出現0.5 cm×1 cm～0.8 cm×1.2 cm皮片壞死；21例郵票狀植皮者，1例出現皮片移動皺縮。除5例骨外露，先通過植皮創面縮小后行皮瓣轉移，101例創面愈合時間7～25 d，平均14 d，無因所植皮片未成活需再次植皮和因感染死亡或截肢。 結論 可調節負壓引流技術結合植皮治療皮膚缺損伴感染創面，可有效控制感染，減輕患者換藥痛苦，減少醫務人員換藥和護理工作量，加快植皮創面愈合，縮短創面治愈時間。
【Abstract】 Objective To explore the correlation between pain grading, stage of necrosis and bone marrow edema(BME) in nontraumatic osteonecrosis of femoral head (NONFH) so as to strengthen understandings about cl inical significance of BME in NONFH. Methods From October 2004 to October 2006, 97 patients (149 hips) with NONFH were treated. There were 68 males and 29 femals with an average age of 38.8 years (19-62 years). The disease course was from 20 days to 4 years. BME was identified grade 0 to grade 2 according to MRI. Based on grading scale of pain, pain grading were divided into no pain (grade 0), mild pain (grade 1) and moderate or severe pain (grade 2). According to Association Research Circulation Osseous staging system, NONFH were divided into I-IV stages. The incidence rate of BME in each pain grading and stages of necrosis was analyzed respectively. Contingency table analyses and rank sum tests were used to compare the difference of pain grading and stages of necrosis among these groups. Results The total incidence rate of BME was 73.15% (109/149), the incidence rateswere 84.38% in pain groups (108 /128) and 94.12% in the grade 2 (32/34). Pain grading correlated with BME rating (P lt; 0.001).The results of rank sum tests for several independent samples showed significant difference in BME among pain groups(P lt; 0.001). With the advance of pain scale, the mean rank of BME increased gradually(28.19 for grade 0, 78.94 for grade 1 and 96.12 for grade 2). BME was more commonly and clearly seen in stage Ⅱ（77.05%）and stage Ⅲ（82.81%）of NONFH. Stage I-III of NONFH correlated with BME rating (P lt; 0.001). The results of rank sum tests showed significant difference in BME rating among three stages (P lt; 0.001). With the advance of disease, the rank of BME rating increased gradually (39.07 for grade 0, 60.16 for grade 1 and 86.15 for grade 2 ). Conclusion BME is a sign that is accompanied with NONFH. The probabil ity and extent of BME correlated well with the pain and stage of NONFH．The condition of BME can be used as a index for the appraisal of advancement of disease and the judgment of treatment result.
目的 研究鹽酸氨基葡萄糖聯合抗骨增生片治療膝骨關節炎（KOA）的可行性及安全性。 方法 2011年1月－2012年8月選取90例KOA患者，按關節面改變部位歸入A組（髕股關節面改變）、B組（脛股關節面改變）、C組（全關節軟骨改變），每組30例。均予以鹽酸氨基葡萄糖、抗骨增生片治療，12周后觀察治療前后臨床療效、綜合療效及安全性等指標及評分。 結果 ① 3組比較，A組療效高于B、C組（P＜0.05）；② A組與B、C兩組在平地行走20 m疼痛評分、關節壓痛度評分和骨關節炎指數（WOMAC）評分方面差異有統計學意義（P＜0.05）；③ A組和B、C兩組在患者自我療效評價、醫生療效評價方面差異有統計學意義（P＜0.05）；④ A組在治療12周后血液血沉、C反應蛋白（CRP）、白細胞介素（IL）-1、IL-6、腫瘤壞死因子-α（TNF-α）較治療前差異有統計表學意義（P＜0.05）；B組則在CRP、IL-6、TNF-α較治療前有差異（P＜0.05）；C組僅在CRP、TNF-α較前有差異（P＜0.05）；⑤3組不良反應發生率則無明顯差異（P＞0.05）。 結論 鹽酸氨基葡萄糖聯合抗骨增生片治療髕股關節面改變的KOA療效優于脛股關節改變，且治療方案可行、安全、優效。